Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Amgen, Inc.; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme.
Clinical Vignette: Managing Multiple Myeloma From Newly Diagnosed to Relapsed/Refractory Settings: An Expert Case-Based Discussion
Release Date: November 30, 2021
Expiration Date: November 30, 2022
Activity Overview
This activity provides hematologists and oncologists with a case-based review of recent clinical trials to allow them to incorporate new agents and regimens safely and appropriately and, thus, optimize the management of patients with MM throughout the course of the disease.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, Inc.; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- integrate patient-specific factors, risk stratification, and treatment history into individualized treatment plans for patients with newly diagnosed and relapsed/refractory MM
- evaluate updated results from pivotal trials on current and emerging therapeutic approaches for the treatment of MM across multiple settings
- develop strategies to identify and mitigate the negative impact of treatment-related toxicities in patients with MM
- apply practice-changing evidence on single agent/combination approaches and updated guidelines to real-world case scenarios of patients with MM
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.Faculty
Director, Clinical Research, Multiple Myeloma Program
Associate Medical Director, Tisch Cancer Institute Clinical Trials Office
Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine, Mt. Sinai New York
Disclosures: Grant Research Support: Janssen Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Amgen, Inc., Pharmacyclics LLC, Seagen Inc., Takeda Oncology; Consultant: Janssen Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Amgen, Inc., Bristol Myers Squibb, Karyopharm Therapeutics, Sanofi Genzyme, Seagen Inc., Oncopeptides, Takeda Oncology, Antengene, GlaxoSmithKline, Secura Bio, Shattuck Labs.
Assistant Professor of Medicine
Director, Myeloma Cellular Immunotherapy
Division of BMT & Cell Therapy
Stanford University
Stanford, CA
Disclosures: Grant Research Support: Amgen, Inc., Bristol Myers Squibb, Janssen Pharmaceuticals, Sanofi Genzyme. Consultant: Magenta Therapeutics, Janssen Pharmaceuticals, Bristol Myers Squibb.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.